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Abstract: Current treatments for diabetic retinopathy (DR) target late stages when vision has already
been significantly affected. Accumulating evidence suggests that neuroinflammation plays a major
role in the pathogenesis of DR, resulting in the disruption of the blood-retinal barrier. Suppressors of
cytokine signaling (SOCS) are cytokine-inducible proteins that function as a negative feedback loop
regulating cytokine responses. On this basis, the aim of the present study was to evaluate the effect of
a SOCS1-derived peptide administered by eye drops (2 weeks) on retinal neuroinflammation and early
microvascular abnormalities in a db/db mouse model. In brief, we found that SOCS1-derived peptide
significantly reduced glial activation and neural apoptosis induced by diabetes, as well as retinal levels
of proinflammatory cytokines. Moreover, a significant improvement of electroretinogram parameters
was observed, thus revealing a clear impact of the histological findings on global retinal function.
Finally, SOCS1-derived peptide prevented the disruption of the blood-retinal barrier. Overall, our
results suggest that topical administration of SOCS1-derived peptide is effective in preventing retinal
neuroinflammation and early microvascular impairment. These findings could open up a new
strategy for the treatment of early stages of DR.
Keywords: diabetic retinopathy; neuroinflammation; suppressors of cytokine signaling; microvascular
impairment; db/db mouse
1. Introduction
Diabetic retinopathy (DR) remains a leading cause of blindness in developed countries. At
present, treatments for DR (i.e., laser photocoagulation, intravitreal injections of anti-VEGF agents or
corticosteroids) are administered in advanced stages of the disease and, therefore early therapeutic
strategies based on a better understanding of the pathogenesis of DR can be envisaged as a more
efficient therapeutic approach [1].
DR has been classically defined as a microvascular complication of diabetes. However, a growing
body of evidence indicates that retinal neurodegeneration is an early event in the pathogenesis of
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DR, which could be linked with the development of microvascular abnormalities [2]. A number of
therapeutic strategies based on the main pathogenic mechanisms involved in neurodegeneration have
been proposed [3]. Systemic administration of drugs blocking these pathways is very unlikely to
reach the retina at pharmacological concentrations and, in addition, could have serious adverse effects.
On the other hand, if the early stages of DR are the therapeutic target, aggressive treatments such as
intravitreal injections would be unacceptable. Topical treatment with neuroprotective agents in the
form of eye drops has been neglected as a possible option because of a general assumption that the
posterior chamber of the eye cannot be reached by this route. However, there is emerging evidence that
several peptides administered by eye drops can reach the retina in pharmacological concentrations, at
least in animal models [4–9]. Apart from allowing self-administration, eye drops limit their action to
the eye and minimize the associated systemic effects.
Inflammation participates in the pathogenesis of both retinal neurodegeneration and microvascular
damage and, therefore, could be envisaged as a key therapeutic target in early stages of DR [10–12].
Among the proinflammatory cytokines involved in the pathogenesis of DR, IL-1β, IL-6, and TNF-α
play a relevant role in the development of DR [13]. The main source of proinflammatory cytokines in
DR is local synthesis by the retina [3], and several studies have pointed out retinal Müller glial cells and
microglia as the initiators of retinal neuroinflammation [14]. Increased levels of these inflammatory
mediators may lead to an early, persistent chronic inflammatory condition in the diabetic retina
resulting in leukocyte activation, adhesion to the vascular endothelium (leukostasis) and disruption
of the blood-retinal barrier (BRB) [15,16], the main cause of diabetic macular edema (DME). Because
cytokines exert profound effects on numerous cell types and cellular processes, cytokine signals are
under stringent control. Suppressors of cytokine signaling (SOCS) proteins are a family of intracellular
cytokine-inducible proteins, consisting of eight members (SOCS1–7 and cytokine-inducible SH2
containing protein), SOCS1 being one of the best characterized [17]. SOCS molecules function as
components of a classical negative feedback loop regulating the initiation, intensity, duration, and
quality of cytokine responses, which are closely linked to the Janus family of intracellular tyrosine
kinases (JAKs) and their substrates, the signal transducers and activators of transcription (STATs).
SOCS1 is rapidly induced following stimulation by several cytokines, and it attenuates cytokine
receptor signaling by its ability to bind and inhibit all four JAK kinases (JAK1–3 and TYK2) [18]. SOCS1
is also a key regulator of M1/M2 macrophage functions [17,18] and a crucial negative regulator of IL-6
and TNF-α, two main cytokines involved in DR. In addition, SOCS1 expression is markedly induced
in retinal cells during ocular inflammation [19]. Our group previously provided direct evidence of a
link between the JAK/STAT/SOCS axis and hyperglycemia-induced cell responses in the kidney [20].
In addition, we recently reported that a cell-permeable peptide mimicking the kinase-inhibitory region
of the suppressor of the cytokine signaling-1 (SOCS1) regulatory protein protects against nephropathy
by suppressing STAT-mediated cell responses to diabetic conditions in vitro and in vivo [21]. Since
JAK/STAT also plays an essential role in the inflammatory process that occurs in the diabetic retina [22],
it is reasonable to postulate that the enhancement of SOCS1 signaling could be a therapeutic target
for DR. On this basis, the main aim of the present study was to evaluate the effect of a SOCS1
peptidomimetic on retinal neurodegeneration and early microvascular abnormalities in the db/db
mouse, an experimental model that reproduce type 2 diabetes.
2. Results
Blood glucose concentrations and body weight during the 2 weeks of treatment were similar in
both db/db mice treated with eye drops containing SOCS1 peptidomimetic and in db/db mice treated
with eye drops containing vehicle.
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2.1. Neuroprotective Effects of Topical Administration of SOCS1 Peptidomimetic
2.1.1. Müller Glial Cells Activation
Glial fibrillar acidic protein (GFAP) expression was mainly confined to the retinal ganglion cell
layer (GCL) in non-diabetic mice (control db/+). The diabetic mice treated with vehicle presented
significantly higher GFAP expression than non-diabetic mice matched by age (Figure 1). It should be
noted that 100% of diabetic mice presented a GFAP score ≥3.
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nuclear layer; INL: inner nuclear layer; GCL: ganglion cell layer. Scale bars, 20 µm. (B) Quantification 
of glial activation based on the extent of GFAP staining. N: 7 mice per group. 
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The presence of Iba-1 positive cells in the retina, a marker of activated microglia, was higher in 
retinas from diabetic mice treated with vehicle than in non-diabetic control mice. In diabetic mice 
treated with SOCS1 peptidomimetic the number of Iba-1 positive cells was significantly reduced in 
comparison with diabetic mice treated with vehicle (Figure 2). 
Figure 1. Effect o topical (eye drops) SOCS1 peptidomimetic (MIS1) administration on glial act vation.
(A) Comp rison of GFAP immunoreactivity (green) in the retina among representativ samples from a
diabetic mouse treated with vehicle, a diabetic mouse treated with eye drops containing MIS1 and a
non-diabetic mouse. Nuclei were labeled with Hoechst (blue). ONL: outer nuclear layer; INL: inner
nuclear layer; GCL: ganglion cell layer. Scale bars, 20 µm. (B) Quantification of glial activation based
on the extent of GFAP staining. N: 7 mice per group.
The administration of the SOCS1 peptidomimetic resulted in a significant decrease of reactive
gliosis, the GFAP score being ≤3 in all cases (Figure 1).
2.1.2. Microglial Activation
The presence of Iba-1 positive cells in the retina, a marker of activated microglia, was higher in
retinas from diabetic mice treated with vehicle than in non-diabetic control mice. In diabetic mice
treated with SOCS1 peptidomimetic the number of Iba-1 positive cells was significantly reduced in
comparison with diabetic mice treated with vehicle (Figure 2).
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Figure 2. Effect of topical (eye drops) SOCS1 peptidomimetic (MIS1) administration on microglial
glial activation. (A) Representative immunofluorescence of Iba-1 (red) in representative mice from
each group. Scale bars, 50 µm. (B) Se iq antitative assessment of microglial activation in the retina
(–: absence of positive cells for Iba-1/power field (20×); +: scattered, 1–3 cell/power field (20×);
++: moderate, 4–10 cells/ power field (20×)). N: 7 mice per group.
2.1.3. Apoptosis
The percentage of apoptotic cells in diabetic mice was significantly higher in comparison to that
observed in retinas from age-matched non-diabetic controls in all retinal layers (Figure 3).
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Figure 3. Effect of topical (eye drops) SOCS1 peptidomimetic (MIS1) administration on apoptosis.
(A) TUNEL positive immunofluorescence (green) in a representative mouse from each group. Scale
bars, 20 µm. (B) Percentage of TUNEL positive cells in the neuroretina. Nuclei were labeled with
Hoechst (blue). ONL: outer nuclear layer; INL: inner nuclear layer; GCL: ganglion cell layer. Black
columns: db/db-vehicle; Gray columns: db/db-MIS1; White columns: db/+. Results are mean ± SD.
*: p < 0.01 in comparison with the other groups. N: 7 mice per group.
Diabetic mice treated with SOCS1-derived peptide presented a significantly lower rate of apoptosis
than diabetic mice treated with vehicle. This result was observed in all retinal layers. No differences
in the percen ages poptotic cells between diabetic mic treated with SOCS1-derived peptide and
non-diabetic mice were observ d.
2.1.4. ERG Abnormalities
The amplitude of a-wave, b-wave and oscillatory potentials (Ops) was significantly lower in
diabetic mice treated with vehicle when compared with non-diabetic mice at several flash intensities
(Figure 4). Concurrently, their implicit time significantly increased in diabetic mice when compared
with non-diabetic mice at several flash intensities. Treatment with SOCS1 peptidomimetic was able to
ameliorate these functional abnormalities induced by diabetes (Figure 4).
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Figure 4. Effect of topical (eye drops) administration of SOCS1 peptidomimetic (MIS1) on ERG
abnormalities. (A) Quantitative analyses of Amplitude and Implicit time of a-wave in db/db treated
with vehicle (n = 10, black square), db/db treated with MIS1 (n = 10, black triangle) and non-diabetic
mice (n = 10, white circle). (B) plitude and Implicit time of b-wave in db/db treated with vehicle
(n = 10, black square), db/db with MIS1 (n = 10, black triangle) and non-diabetic mice (n = 10, white circle).
(C) OPs Amplitude and Implicit time n th experimental groups. Results are mean ± p < 0.05
(db/db treated with vehicle vs. the other groups). # p < 0.05 (db/db treated with vehicle vs. db/db treated
with MIS1). (D) Oscillatory potential traces in response to low, medium and high stimulus intensities
(10 cd·s·m-2, 40 cd·s·m-2 and 80 cd·s·m-2) in a representative non-diabetic mouse (green), a db/db mouse
treated with vehicle (red) and a db/db mouse treated with MIS1 eye-drops (blue).
Int. J. Mol. Sci. 2019, 20, 3615 7 of 20
2.2. SOCS1 Treatment Prevents Vascular Leakage
Higher extravasation of albumin was observed in db/db mice treated with vehicle in comparison
with non-diabetic animals. Treatment with SOCS1-derived peptide prevented albumin leakage in
db/db/mice (Figure 5A,B). The beneficial effect of the topical treatment with SOCS1 peptidomimetic on
vascular leakage was clearly shown by using the Evans Blue method (Figure 5C).
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Figure 5. Effect of topical administration (eye drops) of SOCS1 peptidomimetic (MIS1) on
vascular leakage. (A) Confocal microscopy images showing albumin immunofluorescence (red)
in a representative diabetic mouse treated with vehicle, a diabetic mouse treated with MIS1 and a
non-diabetic (db/+) mouse. Nuclei were labeled with Hoechst (blue). The presence of extravasated
albumin is indicated by arrows. ONL: outer nuclear layer; OPL: outer plexiform layer; INL:
inner nuclear layer; IPL: inner plexiform layer; GCL: ganglion cell layer. (B) Quantification of
albumin immunofluorescence (n = 7 mice per group). AU: arbitrary units. Data are expressed as
mean ± SD. * p < 0.05 (db/db treated with vehicle vs. the other groups). (C) Upper panel: Confocal
immunofluorescence images of vascular permeability assessed by Evans blue dye (red) leakage in
retinal whole mounts. Lower panel: Confocal immunofluorescence images with Spec3 by FV1000,
Olympus. Scale bars, 20 µm. For quantification 3 mice from each group were analyzed.
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2.3. Mechanisms of Action
2.3.1. Glutamate Metabolism
Glutamate levels (µmol/g protein) in the diabetic retinas were higher than in the non-diabetic
retinas (Figure 6A). In diabetic mice treated with SOCS1 peptidomimetic glutamate concentration was
lower than in diabetic mice treated with vehicle, but without reaching statistical significance.
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Figure 6. Effect of topical administration (eye drops) of SOCS1 peptidomimetic (MIS1) on glutamate
and GLAST. (A) Retinal concentration of glutamate measured by HPLC in the experimental groups.
Results are mean ± SD. * p < 0.01 in comparison with the control group. (B) Comparison of GLAST
immunofluorescence (red) between representative samples from a db/db mouse treated with vehicle,
a db/db mouse treated with MIS1 and a non-diabetic mouse. Nuclei were labeled with Hoechst
(blue). ONL: outer nuclear layer; INL: inner nuclear layer; GCL: ganglion cell layer. (C) Quantification
of GLAST immunofluorescence in arbitrary units (A.U). Results are mean ± SD. * p < 0.01 vs. the
other groups.
GLAST, the main glutamate transporter expressed by Müller cells, accounts for at least 50% of
glutamate uptake in the mammalian retina [23]. GLAST content was downregulated in retinas from
diabetic mice treated with vehicle, but in diabetic mice treated with SOCS1 peptidomimetic, GLAST
downregulation was prevented (Figure 6B,C).
2.3.2. Expression of Proinflammatory Cytokines and VEGF
SOCS1 peptidomimetic treatment was able to prevent the overexpression (mRNA and protein) of
IL-1β induced by diabetes (Figure 7A–C).
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Figure 7. Effect of topical administration (eye drops) of SOCS1 peptidomimetic (MIS1) on IL-1β.
(A) Quantification of IL-1β mRNA expression by RT-PCR. Results are mean ± SD. * p < 0.05 in
comparison with the other groups. (B) IL-1β immunofluorescent retinal images obtained by confocal
immunofluorescence from a representative db/db mouse treated with vehicle, a db/db mouse treated
with MIS1 and a non-diabetic (db/+) mouse. (C) Quantification of IL-1β total fluorescence (n = 7 retinas
per group). AU: arbitrary units. Data are expressed as mean ± SD. ONL: outer nuclear layer; OPL:
outer plexiform layer; INL: inner nuclear layer; IPL: inner plexiform layer; GCL: ganglion cell layer.
Alth gh the reduction in mRNA l vels of TNF-α and IL-6 aft r MIS1 treatment was
non-statistically significant, a significant reduction of IL-6 content and perivascular TNF-α deposition
was observed in mice treated with SOCS1 peptidomimetic in comparison with vehicle (Figure 8A–C).
Regarding VEGF, SOCS1 peptidomimetic treatment significantly decreased the overexpression of
VEGF induced by diabetes (Figure 8D).
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2.3.3. SOCS1 Peptide Suppresses STAT Activation and Downstream Gene Expression in Human
Retinal Pigment Epithelial Cells
To confirm the in vivo results, we analyzed the impact of SOCS1 peptide in ARPE-19 cells exposed
to conditions mimicking the diabetic milieu. Confocal microscopy studies revealed that SOCS1 peptide
prevented the phosphorylation and nuclear translocation of STAT1 and STAT3 proteins induced by
IFNγ (Figure 9A) and TNFα (Figure 9A). Real-time PCR demonstrated that ARPE-19 cells responded
to either cytokines or hyperglycemia by upregulating proinflammatory genes such as cytokines (IL-1β
and IL-6) and chemokines (CCL2, CCL5) as well as VEGF, an established inducer of vascular leakage
(Figure 9C–E). Furthermore, pretreatment of cells with SOCS1 peptide resulted in a significant reduction
in the mRNA expression of those genes (Figure 9C–E).
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3. Discussion
In the present study we provide evidence that a SOCS1 peptidomimetic, administered by eye
drops, has dual beneficial effects in terms of neuroprotection and the inhibition of vascular leakage. The
neuroprotective action consisted of a significant reduction of both glial (macroglia and microglia) activation
and apoptosis. Moreover, a significant improvement of electroretinogram (ERG) parameters was observed,
thus revealing the clear impact of the histological findings on global retinal function. The inhibition of
vascular leakage was clearly demonstrated by the SOCS1 peptidomimetic because the disruption of the
BRB, which is an essential step in the development of diabetic macular edema, was prevented.
Many proinflammatory cytokines such as IL-1β, IL-6, IL-8, MCP-1, and TNF-α are upregulated
in the diabetic retina [12,13]. It should be noted that the mean levels of IL-8 and MCP-1 within the
vitreous fluid of diabetic patients have been found in the same range as those reported in pleural
effusions of patients with pneumonia or tuberculosis and they correlated with proliferative DR (PDR)
activity [24]. In addition, the increased vitreous levels of IL-6 and IL-8 correlated with the progression
of PDR and the outcome of vitreous-retinal surgery [25]. Furthermore, the activation of the JAK/STAT
signaling pathway by means of proinflammatory cytokines can lead to angiogenesis either by triggering
angiogenic factors, such as VEGF, or through alternative pathways [26–28]. These findings underscore
inflammation as crucial in the pathogenic events that lead to both early and advanced stages of DR.
The present results define a hitherto unknown therapeutic effect of SOCS1 on the diabetic
retina, and are in good agreement with our previous reports on the efficacy of SOCS1 to prevent
the onset and progression of diabetic nephropathy, a microvascular complication of diabetes that
shares common pathogenic mechanisms with DR [20,21]. Thus, we found that intrarenal delivery
of adenovirus expressing SOCS1 to diabetic rats significantly improved renal function and reduced
renal lesions associated with diabetes, such as mesangial expansion, fibrosis, and the influx of
macrophages [20]. Furthermore, we also demonstrated that the intraperitoneal administration of
the SOCS1 peptidomimetic herein tested in an experimental mouse model of diabetes ameliorated
STAT activity and resulted in reduced serum creatinine levels, albuminuria, and improvement of renal
histologic changes over time. Notably, mice treated with the SOCS1 peptidomimetic also exhibited
reduced leukocyte levels in the kidney and decreased expression levels of proinflammatory and
profibrotic markers that were independent of glycemic and lipid changes [21].
SOCS1 inhibits lymphocyte recruitment into the retina and rats and mice with targeted
over-expression of SOCS1 in the retina are partially protected from experimental autoimmune
uveitis [29]. Furthermore, it has been shown that topical administration of a SOCS1 peptidomimetic
suppresses uveitis and confers protection from ocular pathology during experimental autoimmune
uveitis [30]. These beneficial effects were produced through direct inhibition of immunopathology
mediated by T lymphocytes and by protecting resident ocular cells from apoptosis during chronic
intraocular inflammation [31].
As commented, inflammation plays a major role in the pathogenesis of DR [3,10–12]. In fact,
corticosteroids (intravitreal injections or implants) are indicated in advanced stages of DME. However,
when the early stages of DR are the therapeutic target, it would be inconceivable to recommend an
aggressive treatment such as intravitreal injections. In this regard, it has been reported that topical
administration of corticosteroids and NSAIDs could be useful for treating DME [32,33]. However, a
lack of effect in reducing retinal thickness after one year of topical administration of nepafenac was
also reported [34].
Besides being a non-invasive route, the advantage of topical administration is that it ensures low
systemic absorption, thus minimizing the associated systemic effects. In this regard, the negligible
level of systemic absorption of a SOCS1 peptide after its topical administration has been demonstrated
by the absence of inhibitory effects on peripheral immune responses [31].
Regarding the mechanisms involved in the beneficial effect of the SOCS1 peptidomimetic, we
found that it reduces the upregulation of IL-1β, IL-6, TNF-α, and VEGF induced by diabetes. It should
be noted that IL-1β is a pivotal inflammatory cytokine because it is able to activate nuclear factor-κB,
Int. J. Mol. Sci. 2019, 20, 3615 13 of 20
the transcription factor which in turn governs the production of other proinflammatory cytokines [35]
and plays a significant role in the degeneration of retinal capillaries induced by diabetes [36]. TNF-α
downregulates tight junction proteins of endothelial cells and it is also required for VEGF-induced
leakage, thus participating in the breakdown of the BRB, which is the main pathogenic factor of
DME [37]. We found that TNF-α expression in diabetic mice treated with vehicle was mainly detected in
the perivascular areas of the inner retina. Supporting this finding, it has been reported that in the early
stages of DR, advanced glucose end products (AGEs) stimulate perivascular microglial cells to produce
TNF-α [38]. It has recently been described how TNFα alone induces small-molecule permeability of
the BRB in vitro, whereas the combination of TNFα, IL-1β, and VEGF induces permeability to large
molecules [39]. In addition, we found that SOCS1 peptidomimetic suppressed STAT activation in RPE
cells, thus downregulating the expression of IL-1β, IL-6, CCL2, and CCL5, as well as the expression of
VEGF. The combination of anti-inflammatory and anti-VEGF action of SOCS1 peptidomimetic observed
in the present study is an extra-value in targeting two essential events in the pathogenesis of DR.
However, the design of our study does not permit us to know whether the effect on VEGF is directly
mediated by the peptidomimetic SOCS1 or by the downregulation of proinflammatory cytokines.
The extracellular accumulation of glutamate plays a key role in the excitotoxicity, which plays a
crucial role in neuron death induced by diabetes [2]. GLAST is the main transporter of extracellular
glutamate and, therefore, GLAST downregulation induced by diabetes results in high extracellular
glutamate levels, thus contributing to neurodegeneration [2]. In the present study, we provide evidence
that SOCS1 avoids the increase in retinal glutamate levels and that this is associated with a dramatic
inhibition of diabetes induced GLAST downregulation. Therefore, the preservation of GLAST seems
one of the main mechanisms by which SOCS1 peptidomimetic decreases the levels of extracellular
glutamate. It is worth mentioning that we found that a GLAST mediated reduction of glutamate
accumulation is a common mechanism of drugs with associated anti-inflammatory activity [5,6,8,40].
In this regard, inflammatory cytokines such us TNF-α have been shown to interact with glutamate
pathways in several important ways, including decreasing the expression of glutamate transporters
on relevant glial elements and increasing the release of glutamate from astrocytes in the brain [41].
Therefore, the inhibition of TNF-α induced by SOCS1 peptidomimetic could also participate in reducing
extracellular glutamate levels. However, specific experiments to confirm this hypothesis are needed.
The primary neuroinflammatory action of SOCS1 peptidomimetic suggests that it could be more
effective when inflammation is a predominant event in the pathogenesis of DR. Recently there has been
an increasing interest in the determination and validation of non-invasive imaging retinal parameters,
as possible biomarkers of a local retinal “inflammatory condition” in DR and DME [42]. The most
important imaging modalities have been spectral domain (SD)-OCT and fundus autofluorescence (FA).
These imaging biomarkers include: subfoveal neuroretinal detachment and hyperreflective retinal
spots/foci evaluated on SD-OCT, and foveal hyperautofluorescence evaluated on FA. These methods
could be useful for identifying a subset of the diabetic population in which inflammation plays an
essential pathogenic role in DR. In addition, they could be useful in prognosis and in predicting
treatment response. This is important in the era of personalized or precision medicine.
The present study has several limiting factors such as the lack of dose-efficacy studies, formulation
stability analyses, and specific assessments addressed to evaluate potential ocular and systemic toxicity.
Therefore, further research aimed at evaluating these important issues is needed. In conclusion, our
results suggest that blocking retinal neuroinflammation by topical administration of SOCS1-derived
peptide could be a new strategy for the treatment of DR. However, specific clinical trials aimed at
evaluating its safety and effectiveness are needed.
4. Materials and Methods
4.1. Animals
The neuroprotective effect of SOCS1 peptidomimetic was tested in a db/db mouse model. This
mouse carries a mutation in the leptin receptor gene and is a model for obesity-induced type 2 diabetes.
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Our group previously reported that the db/db mouse reproduces the features of the neurodegenerative
process that occurs in the human diabetic eye [26] and has been used for testing the capacity of several
drugs in reducing neuroinflammation and vascular leakage [6,8,40].
A total of 20 male db/db (BKS.Cg-Dock7m +/+ Leprdb/J) mice aged 8 weeks were purchased
from Charles River Laboratories, Inc. In addition, 10 non-diabetic db/+ (BKS.Cg-Dock7m + Leprdb/+)
mice matched by age were used as a control group. The animals were randomly housed under tight
environmental conditions of humidity (60%), temperature (20 ◦C) and cycles of 12 h/12 h light/darkness.
They had free access to filtered water and “ad libitum” food.
SOCS1 peptidomimetic (10 mg/mL; 5 µL twice/daily) (n = 10) or vehicle (PBS; 5 µL twice/daily)
(n = 10) eye drops were administered directly onto the superior corneal surface of each eye using a
micropipette in 8 weeks-old mice. Ten non-diabetic mice matched by age served as the control group.
The treatment (MIS1 or vehicle) was administered twice daily for 15 days. On day 15, the drop of MIS1
or vehicle was administered approximately two hours prior to necropsy. Mice were euthanized by
cervical dislocation and the eyes were immediately enucleated. The dose of SOCS1 was selected based
on our previous experience using the intraperitoneal route for treating diabetic nephropathy [21].
For the Evans Blue assay, a set of animals (n = 3 per group) were intravenously injected in
the tail with a solution of Evans Blue (E2129 SIGMA) (17 mg/Kg body weight, in concentration
5 mg/mL dissolved in saline solution sterile). Immediately after injection, the animals visibly turned
blue, confirming dye uptake and distribution. After 120 min, the mice were euthanized by cervical
dislocation and the eyes were enucleated. The retinas of each animal were isolated, weighed and
rapidly protected from light. Flat-mounted slides were obtained, and cover slipped with a drop of
mounting medium Prolong Gold antifade reagent (Invitrogen, Carlsbad, CA, USA; Thermo Fisher
Scientific, Waltham, MA, USA). Digital images from different random fields of all retinas were acquired
using a confocal laser scanning microscope (FV1000; Olympus, Hamburg, Germany) at ×20 using the
561-nm laser line, and each image was recorded with identical beam intensity at the size of 1024 pixels
× 1024 pixels. For quantitative analysis of the albumin-bound Evans Blue, Z-stacks retinal images
(step size 1.16 µm) of different regions of the vascular tree were acquired. To remove the eye artefacts
caused by the sample procedures, projections of the middle Z-plane images were analyzed with the
magic wand tool (tolerance 120, eight pixels connected) of Fiji software (https://fiji.sc).
This study was approved by the Animal Care and Use Committee of VHIR (Vall d’Hebron
Research Institute, CEEA 75/15, September 2015)). All the experiments were performed in accordance
with the tenets of the European Community (86/609/CEE) and ARVO (Association for Research in
Vision and Ophthalmology).
4.2. SOCS1 Derived Peptide (MIS1)
The cell-permeable MIS1 peptide containing the kinase inhibitory region of mouse SOCS1 (residues
53–68) was synthesized in solid phase using the 9-fluorenylmethoxycarbonyl strategy (Proteogenix,
ProteoGenix, Schiltigheim, France), then dissolved in 1% DMSO in saline solution, filter-sterilized and
stored at −80 ◦C until use.
4.3. Electroretinogram
Full field electroretinography (ERG) recordings were measured using the Ganzfeld ERG platform
(Phoenix Research Laboratories, Pleasanton, CA, USA) following ISCEV (International Society for
Clinical Electrophysiology of Vision) recommendations [43]. Three ERG components were assessed in
terms of amplitude and timing: a-wave, b-wave, and oscillatory potentials (OPs). We added up OPs
amplitudes (ΣOPs amplitude) and implicit time (ΣOPs implicit time) for the first 5 OPs.
4.4. Immunofluorescence Analysis
For immunohistochemical analysis, animals were intraperitoneally injected with 0.2 mL of
anesthesia (proportion of solution was 1 mL ketamine and 0.3 mL xylazine) and transcardially perfused
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with p-formaldehyde 4%. The ocular globes were immediately enucleated, fixed in p-formaldehyde
4% for 6 h and embedded in paraffin blocks. The paraffin blocks were cut along the eye axis with a
microtome and the sections of 4 µm were mounted on positive charged slides and stored at 4 ◦C. The
sections used for immunofluorescence analyses (6 sections per retina) were obtained from central retina.
Paraffin-embedded sections were deparaffinized in xylene and rehydrated in a graded ethanol series.
The sections were fixed in ice-cold acid methanol for 1 minute and washed with 0.01 M phosphate
buffered saline (PBS) at pH 7.4. Subsequently, antigen retrieval was performed. The sections were
immersed in an antigen retrieval solution (sodium citrate 10 mM, pH 6.0) and heated in a pressure
cooker at 150 ◦C for 4 min. They were blocked by the corresponding blocking solution for 1 h at
room temperature and were incubated overnight at 4 ◦C with the corresponding primary antibodies
described in Table 1. Next day, they were washed twice in PBS, and incubated for 1 h in darkness at
room temperature along with secondary antibodies sections (Alexa 488 or Alexa 594; 1:600, Molecular
Probes (Eugene, OR, USA). The sections were washed in PBS, counterstained with Hoechst (1:500) and
coverslipped using a mounting solution (Prolong Gold antifade reagent Invitrogen, Thermo Fisher
Scientific). Images were acquired with a confocal laser scanning microscope (FV1000; Olympus). Five
fields (three corresponding to the central and two to the peripheral retina) from each section were
analyzed. The same locations and number of fields were measured in all retinas. The fluorescence
intensity of the images was quantified by ImageJ.
Table 1. Targets, dilution, blocking conditions and sources of applied primary antibodies
in immunofluorescence.
Target Molecule Clone Blocking Conditions Dilution Manufacturer
GFAP Rabbit polyclonal 10% NGS, 1% BSA in PBS pH 7.4 1/200 Abcam (ab7260)
Iba-1 Rabbit polyclonal 5% NGS, 0.1% Triton X-100 in PBSpH 7.4 1/100 Wako (019-19741)
GLAST (EAAT1) Rabbit polyclonal 5% NGS, 0.3% Triton X-100, 3% BSAin PBS pH 7.4 1/100 Abcam (ab416)
IL-1β Rabbit polyclonal 5% NGS, 0.1% Triton X-100, 1% BSAin PBS pH 7.4 1/100 Abcam (ab9722)
IL-6 Rabbit polyclonal 10% NGS, 0.3% Triton X-100, 3%BSA in PBS pH 7.4 1/200 Abcam (ab6671)
TNF-α Mouse monoclonal 10% NGS, 0.1% Triton X-100,1%BSA in PBS pH 7.4 1/100 Abcam (ab8348)
VEGF Rabbit polyclonal 10% NGS, 0.1% Triton X-100,1%BSA in PBS pH 7.4 1/200 Abcam (ab46154)
Serum Albumin Sheep polyclonal 2.5% non-fat milk in PBS pH 7.4 1/ 500 Abcam (ab8940)
NGS: Normal goat serum; BSA: Bovine serum albumin; PBS: Phosphate-buffered saline.
4.4.1. Analysis for Glial Activation
Glial activation was evaluated by fluorescence microscopy using specific antibodies against GFAP
(Glial fibrillar acidic protein). To evaluate the degree of glial activation, we used a scoring system
based on the extent of GFAP staining [44] and previously used by our group [26] (Table 2).
Microglial activation was evaluated based on Iba-1 staining and analyzed by a semiquantitative
score. Semiquantitative assessment of microglial activation in the retina: (–) absence of positive cells
for Iba-1/power field (20×); (+) scattered, 1–3 cell/power field (20x); (++) moderate, 4–10 cells/ power
field (20×).
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Table 2. Scoring system based on the extent of GFAP staining.
GFAP Score Description
1 Müller cell endfet region/GCL only
2 Müller cell endfeet region/GCL plus a few proximal processes
3 Müller cell endfeet plus many processes, but not extending to ONL
4 Müller cell endfeet plus processes throughout with some in the ONL
5 Müller cell endfeet plus lots of dark processes from GCL to outer margin of ONL
4.4.2. Apoptosis Assessment
Apoptosis was evaluated using the TUNEL (Terminal Transferase dUTP Nick-End Labeling)
Dead-end Fluorometric System method (Promega Corporation, Madison, WI, USA). Briefly, sections of
retina were permeabilized by incubation at room temperature for 1 min with 20 µg/mL Proteinase
K solution, freshly prepared. The sections were washed in PBS, counterstained with Hoechst (1:500)
and cover slipped using a mounting solution (Prolong Gold antifade reagent Invitrogen, Thermo
Fisher Scientific). Apoptotic cells were identified by green fluorescein -12-dUTP -labeled DNA with
488 nm as excitation wavelength and the range for detecting positive cells in the confocal laser scanning
microscope was 515–565 nm (green). Lastly, the number of green positive cells and total cells (in blue)
was counted.
4.5. Measurement of Retinal Vascular Permeability
Retinal vascular permeability was examined by assessing the albumin leakage from blood
vessels into the retina by both albumin immunofluorescence analyses and the Evans blue-albumin
method (ex-vivo). The Evans blue-albumin method was used as previously described with some
modifications [45–47]. Digital images from different random fields of all retina were acquired with a
confocal laser scanning microscope (FV1000, Olympus. Hamburg, Germany) at 20× using the 561 nm
laser line and each image was recorded with identical beam intensity at a size of 1024 × 1024 pixels.
4.6. Glutamate Quantification
Quantification of glutamate was performed by reverse phase ultra-performance liquid
chromatography (UPLC) (Acquity-UPLC, Waters, Milford, MA, USA) as aminoquinoline derivatives
(AccQTag chemistry, Mass Trak AAA method and instruments, Waters), following the methodology
previously described by Narayan et al. [48].
4.7. Measurements of Cytokine Expression
Total RNAs were extracted from retinas using Trizol reagent (Invitrogen) according to the
manufacturer’s instructions. The quality and concentration of RNAs were determined with a Nanochip
(Agilent Technologies, Madrid, Spain) and a Nanodrop ND-1000 spectrophotometer (Thermo Fisher
Scientific). cDNA reactions were performed in a 2720 Thermal Cycler with High Capacity kit reagents
(Applied Biosystems, Foster City, CA, USA). Real-Time PCRs were carried out using SYBR Green PCR
Master Mix (Applied Biosystems) in the 7.900 HT Sequence Detection System with 384-well optical
plates. Each sample was assayed in duplicate, and negative controls were included.
Specific mouse primers for IL-1β were: forward 5′-GCAACTGTTCCTGAACTCAACT-3′ and
reverse 5′-ATCTTTTGGGGTCCGTCAACT-3′. ABI SDS 2.0 RQ software and the 2−∆∆Ct analysis
method were used for relative quantification (R.Q.) calculation with mouseβ-actin as endogenous control
(Forward: 5′-CTAAGGCCAACCGTGAAAG-3′ and reverse 5′-ACCAGAGGCATAC AGGGACA-3′).
4.8. In Vitro Studies
Adult Retinal Pigment Epithelial cell line-19 (ARPE-19; kindly provided by S. de Pascual-Teresa,
ICTAN-CSIC, Madrid, Spain) were cultured in DMEM:F12 (1:1) medium containing 10% fetal bovine
Int. J. Mol. Sci. 2019, 20, 3615 17 of 20
serum (FBS), 100 U/mL penicillin, 100µg/mL streptomycin and 2 mmol/L l-glutamine (Life Technologies,
Rockville, MD, USA). Serum-starved cells were pretreated for 90 min with SOCS1 peptide (100 µg/mL)
before stimulation with either interferon- (IFNγ 10 ng/mL) or tumor necrosis factor-α (TNFα 10 ng/mL)
for 180 min. In other experiments, cells were maintained in medium containing low-glucose (5 mmol/L
d-glucose), then pretreated with SOCS1 peptide and cultured for an additional 48 h under high-glucose
conditions (30 mmol/L d-glucose).
Total RNA was extracted with Tryzol (Life Technologies). Gene expression levels were analyzed
by real-time quantitative PCR using Taqman gene expression assays (Il1β-Hs01555410, Il6-Hs00174131,
Ccl2-Hs00234140, Ccl5-Hs00174575 and Vegf-a-Hs00900055; Applied Biosystem) and normalized to
18S housekeeping gene.
For immunofluorescence analysis, cells were seeded at 104/well onto glass coverslips. After
stimulation, cells were subsequently fixed in 4% paraformaldehyde, permeabilized in 0.1% sodium
citrate/0.1% Triton X-100 for 5 min and blocked for 1 h in 2% bovine serum albumin and 6% host
serum. Then cells were incubated with primary antibodies against phosphorylated STATs (P-STAT1,
Tyr701, 1:250, Invitrogen; P-STAT3, Ser727, 1:250, Invitrogen) followed by conjugated secondary
antibodies (Alexa Fluor 568; Invitrogen) and nuclear counterstaining (4’,6-diamidino-2-phenylindole;
Sigma-Aldrich, Madrid, Spain). Images were captured using a confocal fluorescent microscope (Leica,
Barcelona, Spain).
4.9. Statistical Analysis
The results are expressed as mean ± SD. Statistical comparisons were performed with Student′s
unpaired t test. When multiple comparisons were performed, one-way ANOVA followed by
Bonferroni’s test was used. The Fisher’s exact test was used to analyze categorical variables. Levels of
statistical significance were set at p <0.05.
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Abbreviations
AGEs Advanced glucose end products
BRB Blood-retinal barrier
DME Diabetic macular edema
DR Diabetic retinopathy
ERG Electroretinogram
GCL Ganglion cell layer
GFAP Glial fibrillar acidic protein
GLAST Glutamate-aspartate transporter
JAKs Janus family of intracellular tyrosine kinases
INL Inner nuclear layer
MIS1 SOCS1 peptidomimetic
ONL Outer nuclear layer
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OPs Oscillatory potentials
SOCS Suppressors of cytokine signaling
STATs Signal transducers and activators of transcription
TUNEL Terminal Transferase dUTP Nick-End Labeling
VEGF Vascular endothelial growth factor
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